Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Results from several long-term (>5 years) safety analyses have been recently published, with the inherent evidence substantially confirming the findings from previous trials. The clinical experience gained over the years in the use of trastuzumab has also fueled a number of observational studies focused on the effectiveness of this drug in the real-world settings. We herein reviewed the evidence available from tree major databases, namely, PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), to explore and critically discuss key issues related to the long-term safety and effectiveness of trastuzumab in clinical practice.

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer / Mazzotta, Marco; Krasniqi, Eriseld; Barchiesi, Giacomo; Pizzuti, Laura; Tomao, Federica; BARBA, MADDALENA; Vici, Patrizia. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:2(2019). [10.3390/jcm8020254]

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer

Mazzotta, Marco;Barchiesi, Giacomo;Pizzuti, Laura;Tomao, Federica;BARBA, MADDALENA;
2019

Abstract

Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Results from several long-term (>5 years) safety analyses have been recently published, with the inherent evidence substantially confirming the findings from previous trials. The clinical experience gained over the years in the use of trastuzumab has also fueled a number of observational studies focused on the effectiveness of this drug in the real-world settings. We herein reviewed the evidence available from tree major databases, namely, PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), to explore and critically discuss key issues related to the long-term safety and effectiveness of trastuzumab in clinical practice.
HER2 positive breast cancer; efficacy; long-term safety; real-world settings; trastuzumab
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer / Mazzotta, Marco; Krasniqi, Eriseld; Barchiesi, Giacomo; Pizzuti, Laura; Tomao, Federica; BARBA, MADDALENA; Vici, Patrizia. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:2(2019). [10.3390/jcm8020254]
File allegati a questo prodotto
File Dimensione Formato  
Mazzotta_Long-term_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 660.94 kB
Formato Adobe PDF
660.94 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1307288
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact